BIOSYNEX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.04 EUR | +1.13% |
|
-0.49% | -51.62% |
| May. 28 | Biosynex: obtains CE markings under the new IVDR regulations | CF |
| May. 13 | Biosynex: Oren Bitton appointed Chief Operating Officer | CF |
| Sales 2022 | 197M 213M | Sales 2023 | 92.98M 101M | Capitalization | 85.85M 93.16M |
|---|---|---|---|---|---|
| Net income 2022 | 15M 16.28M | Net income 2023 | -36M -39.07M | EV / Sales 2022 | 0.54 x |
| Net cash position 2022 | 35.09M 38.08M | Net Debt 2023 | 39.8M 43.19M | EV / Sales 2023 | 1.35 x |
| P/E ratio 2022 |
9.08
x | P/E ratio 2023 |
-2.42
x | Employees | 569 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.43% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.08% | ||
| 1 week | -1.72% | ||
| Current month | -4.88% | ||
| 1 month | -2.32% | ||
| 3 months | -35.67% | ||
| 6 months | -53.82% | ||
| Current year | -52.16% |
1 week
3.97
4.10
1 month
3.974.24
Current year
3.928.97
1 year
3.9211.00
3 years
3.9228.78
5 years
2.5230.38
10 years
2.0930.38
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Lamy
FOU | Founder | - | 05-03-14 |
Larry Abensur
CEO | Chief Executive Officer | 69 | 05-03-14 |
Thierry Paper
FOU | Founder | 60 | 05-03-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thierry Paper
FOU | Founder | 60 | 05-03-14 |
Thomas Lamy
FOU | Founder | - | 05-03-14 |
Larry Abensur
CEO | Chief Executive Officer | 69 | 05-03-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 4.04 | +1.13% | 11,409 |
| 24-05-28 | 3.995 | -2.08% | 3,534 |
| 24-05-27 | 4.08 | -0.49% | 14,880 |
| 24-05-24 | 4.1 | +1.23% | 3,121 |
| 24-05-23 | 4.05 | -0.25% | 2,479 |
Real-time Euronext Paris, May 28, 2024 at 11:35 am EDT
More quotes
Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas:
- manufacturing of diagnosis tests for own account;
- sale of diagnosis tests supplied by other manufacturers of semi-finished products;
- research and development services for third party;
- sale of licenses;
- sale of biological reagents.
At the end of 2023, the group had one production site located in France.
France accounts for 56.5% of net sales.
| 1st Jan change | Capi. | |
|---|---|---|
| -52.16% | 46.76M | |
| -6.41% | 12.1B | |
| -4.07% | 8.14B | |
| +5.77% | 5.72B | |
| +28.13% | 5.51B | |
| -59.44% | 2.72B | |
| +8.04% | 2.59B | |
| -6.47% | 2.34B | |
| +21.84% | 2.11B | |
| -8.15% | 1.79B |
- Stock Market
- Equities
- ALBIO Stock
